Abbreviated Name

Proteomics Biomarker Development Laboratory

Lead Investigator

No lead investigator

Coordinating Investigator

No coordinating investigator

Involved Investigators

• No involved investigators

Abstact

The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply technologies for protein analysis to the detection and identification of proteins secreted by tumor cells and protein antigens that induce a humoral response in tumor s. The initial targeted tumor types for the identification of potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver. The proposed studies will make heavy utilization of two-dimensional (2-D) protein analysis, of protein identification technologies and of database capabilities that have been developed by the applicant group. The objectives of this research are to 1. Identify tumor antigens that induce a humoral response; 2. Identify tumor secreted proteins and develop a database; 3. Preliminarily validate the potential utility of markers for early cancer detection. Sixty ml of blood will be obtained from healthy normals, and from small cell lung cancer, hepatoma, esophageal, and breast cancer patients, and from ovarian, colon, and non-small cell lung cancer patients prior to surgical resection and six to ten weeks after resection. Demographic data, sera and DNA will be used in 2-D protein analysis to identify new or altered proteins. The initial validation will be the assay of the presence or absence of a given protein in a large sample cohort from the samples collected from these patients. There is no specified age range, although the diseases under study do not occur in children. No subjects will be excluded on the basis of race or gender. Women of child bearing age will be studied. Linkable demographic data will be held separately from the bar-coded serum or DNA samples. Serum and DNA sample will be identifiable only by subject identification number. Full written informed consent will be obtained from patients.

Aims

Analytic Method

Biomarkers

• No biomarkers available at this time for this protocol

Data Collections

• No data collections available at this time for thie protocol

Protocol ID

53

Protocol Type

Single

Field of Research

UNKNOWN

Collaborative Group

(No collaborative group)

Cancer Types

• (No cancer types specified)